Nanobiotix hosts virtual discussion on the potential of NBTXR3 in cancer treatments

Paris, France ; Cambridge, Massachusetts (United States); June 12, 2024. French biotechnology company Nanobiotix announces a virtual expert discussion on June 18, 2024 from 3:00 p.m. to 4:30 p.m. CEST. The event will bring together several Key Opinion Leaders (KOLs) to discuss the potential of NBTXR3 in immunotherapy, including for head and neck cancer and other indications.

Speakers will include Dr. Colette Shen and Dr. Ari Rosenberg, study 1100 investigators, and Dr. Jeffrey Bockman as moderator. They will be accompanied by Dr. Sébastien Paris, Nanobiotix expert. The discussion will focus on recent data published at the ASCO Annual Meeting, showing a positive response of patients treated with radiotherapy-activated NBTXR3 followed by anti-PD-1.

Topics covered will include the mechanism of action of NBTXR3, its local and systemic response, and the needs of patients with head and neck cancer. Participants can register via the Nanobiotix website and email their questions.